Swiss-Certified Medical Cannabis Production

MA Switzerland produces high-grade cannabis flowers for pharmaceutical applications under full SwissMedic authorization, applying GACP cultivation, GMP-aligned post-harvest processes, and rigorous quality assurance across every stage.

A Swiss pharmaceutical-grade cannabis producer

At MA Switzerland, we specialize in the controlled cultivation of medical-grade cannabis with THC >1.0%, operating under the strict regulatory framework defined by SwissMedic.
Our facility in Ticino combines advanced environmental controls, precision-agronomy, and certified quality systems to ensure medical-grade consistency in every harvested batch.

We supply licensed pharmaceutical partners, pharmacies, and medical institutions through controlled, fully traceable, and compliant production cycles.

Certified Excellence: Our Regulatory Standards

SwissMedic Licensed

We hold a SwissMedic operating licence for the cultivation of medical cannabis under Art. 2(h) OCStup, ensuring full compliance with national narcotics legislation.

GACP-Compliant Cultivation

From genetics selection to harvest, all horticultural activities follow Good Agricultural and Collection Practices (GACP), guaranteeing botanical consistency and patient safety.

GMP-Aligned Processing

Post-harvest steps—including trimming, controlled drying, and bulk preparation—follow GMP principles to support downstream pharmaceutical workflows.

Full Traceability & Auditability

We maintain complete tracking of plants, batches, and harvest data, aligned with SwissMedic reporting (NDS-WEB, MESA, JARE).

What We Produce

We cultivate selected high-THC cannabis varieties for medical and pharmaceutical use, optimized for cannabinoid stability, terpene preservation, and consistent yield parameters. Our production is intended exclusively for licensed pharmaceutical processors and pharmacies authorized to handle controlled substances.

Our flowers are cultivated to meet strict pharmaceutical expectations. They typically reach THC levels between 16% and 30%, falling within the medical-grade category, and are obtained exclusively from controlled indoor cultivation environments. Each batch is free from pesticides and heavy metals, and undergoes rigorous microbiological testing in line with pharmacopeial standards. The product is supplied in bulk, ready for subsequent pharmaceutical processing.

Latest News

GACP and GMP requirements in the production of medical Cannabis flowers in Switzerland

19.11.2025

Switzerland distinguishes clearly between GACP and GMP in the production of medical cannabis. GACP governs cultivation and minimal post-harvest handling, which remain under narcotics law (OCStup) and do not require Swissmedic certification. GMP applies as soon as any pharmaceutical-relevant transformation occurs, triggering LPTh licensing requirements such as extraction, decarboxylation, purification, moisture adjustment, QC testing, and API release. Cultivators operate under OCStup licences, while pharmaceutical manufacturers must hold LPTh establishment licences and comply fully with GMP. This separation ensures a transparent, compliant chain from plant cultivation to medicinal product preparation.

Learn more

Medical Cannabis License Framework In Switzerland

Understanding the Swissmedic’s license

19.11.2025

Switzerland’s medical cannabis sector operates under a tightly structured framework that places cannabis with THC ≥1.0% in Table A of the OTStup-DFI and under the direct supervision of Swissmedic, which acts as the national Cannabis Agency. Cultivation requires both an operating licence and a crop-specific authorisation, with strict obligations for traceability and minimal permitted post-harvest handling. Pharmaceutical operators must hold appropriate LPTh and OCStup licences, advertising is heavily restricted, and annual JARE reporting ensures continuous monitoring of stocks, harvests, and deliveries. Import and export flows are controlled through Single Permits, ensuring compliance with both national legislation and international narcotics conventions.

Learn more

A new chapter for the MA Switzerland group

11.11.2025

MA Switzerland Production Sagl has obtained Swissmedic authorization for the cultivation of medical cannabis, a major milestone that complements its CBD production – active since 2018 – and opens new opportunities in the Swiss therapeutic sector.

Learn more

View all articles